MorphoSys AG (NASDAQ:MOR – Get Rating)’s share price gapped down before the market opened on Wednesday . The stock had previously closed at $3.93, but opened at $3.74. MorphoSys shares last traded at $3.75, with a volume of 2,237 shares changing hands.
Wall Street Analyst Weigh In
A number of research analysts recently weighed in on MOR shares. Citigroup downgraded shares of MorphoSys from a “neutral” rating to a “sell” rating in a research report on Tuesday. Stifel Nicolaus downgraded shares of MorphoSys from a “buy” rating to a “hold” rating in a research report on Tuesday. Deutsche Bank Aktiengesellschaft downgraded shares of MorphoSys from a “hold” rating to a “sell” rating in a research report on Monday, October 24th. Finally, Morgan Stanley increased their price objective on shares of MorphoSys from €26.00 ($26.80) to €28.00 ($28.87) and gave the company an “equal weight” rating in a research report on Friday, July 29th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, MorphoSys has a consensus rating of “Hold” and a consensus target price of $32.50.
MorphoSys Stock Up 3.4 %
The company has a debt-to-equity ratio of 2.01, a current ratio of 2.98 and a quick ratio of 2.91. The firm has a market capitalization of $546.34 million, a P/E ratio of -0.56 and a beta of 0.99. The company’s 50-day simple moving average is $4.97 and its two-hundred day simple moving average is $5.10.
Institutional Inflows and Outflows
MorphoSys Company Profile
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.
- Get a free copy of the StockNews.com research report on MorphoSys (MOR)
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ’s Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.